GLP-1 drugs were built to move a number on a scale. What the SELECT trial showed in 2023 is that at least one of them also moves a number that matters more: your risk of a heart attack or stroke. This guide breaks down what the cardiovascular data actually says, which drugs it applies to, and how to use it if you're already on a GLP-1 or considering one.
- SELECT (NEJM, Aug 2023, n=17,604) found semaglutide 2.4mg cut major adverse cardiovascular events by 20% in adults with existing cardiovascular disease and overweight or obesity, without diabetes.
- Tirzepatide doesn't yet have a completed cardiovascular outcomes trial matching SELECT's design — its heart benefit is inferred, not proven.
- The cardiovascular benefit curves split from placebo within months, before most participants had lost significant weight.
- Trial averages showed systolic blood pressure down 3-6 mmHg and resting heart rate up roughly 2-4 bpm.
- The 20% MACE reduction applies specifically to people with established cardiovascular disease, not a general weight-loss population.
TL;DR
The SELECT trial (NEJM, August 2023, n=17,604) found that semaglutide 2.4mg — the Wegovy dose — cut major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity, even without diabetes. That's the strongest evidence for glp-1 cardiovascular benefits to date. Tirzepatide (Zepbound) doesn't have an equivalent completed cardiovascular outcomes trial yet, so its heart-protective claim is inferred, not proven. Verdict: semaglutide has trial-confirmed cardiovascular benefit in a specific population; tirzepatide's benefit is still a hypothesis.
Why this matters
Most people start a GLP-1 for weight loss and assume the cardiovascular upside comes along for free. It doesn't, automatically. The SELECT trial mattered because it separated the drug's cardiovascular effect from the weight loss effect — the benefit curves split apart within months, before most participants had lost significant weight. That points to something happening at the vessel and inflammation level, not just less body mass to move around. If you're on a GLP-1 for aesthetic or metabolic reasons, knowing whether you fit the population that trial studied changes how your clinician should frame your risk conversation in 2026.
What to gather before this conversation matters
- Your cardiovascular history — prior heart attack, stroke, peripheral artery disease, or none of the above
- Current lipid panel — LDL, HDL, triglycerides, ideally drawn within the last 6 months
- Blood pressure readings — at least three separate readings, not one office visit
- A1c or fasting glucose — determines whether you're in the diabetic, prediabetic, or metabolically normal bucket that trials study separately
- Which GLP-1 you're on or considering — semaglutide and tirzepatide have different evidence bases, and choosing between tirzepatide and semaglutide should account for that gap
- A clinician who will actually read your labs, not just refill a prescription
The steps
1. Establish your baseline cardiovascular risk
You can't measure a benefit against a risk you haven't quantified. A clinician should calculate a 10-year ASCVD risk score using your age, blood pressure, cholesterol, and smoking status before you start any GLP-1. Skipping this step means you'll never know if the drug actually moved your risk or if it just looks that way.
Common mistake: treating a normal blood pressure cuff reading at one visit as your baseline. Trials use averaged readings across multiple visits for a reason — single readings swing 10-15 mmHg on stress or caffeine alone.
2. Understand exactly what the SELECT trial proved
SELECT enrolled 17,604 adults, average age 61, with existing cardiovascular disease and overweight or obesity, but without diabetes. Over roughly 3 years, semaglutide 2.4mg reduced the composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% versus placebo. That's a secondary prevention result — it applies to people who already have heart disease, not a general population claim.
3. Know what's proven for tirzepatide versus assumed
Tirzepatide (marketed as Zepbound for weight loss, Mounjaro for diabetes) does not yet have a completed cardiovascular outcomes trial matching SELECT's design. A trial is underway, but results aren't published as of 2026. If your clinician implies tirzepatide carries the same proven cardiovascular benefit as semaglutide, that's an assumption dressed as a fact — worth a direct question at your next visit. Ozempic and Wegovy share the same molecule and dosing history, which is part of why semaglutide's cardiovascular data is more mature than tirzepatide's.
Semaglutide vs. tirzepatide cardiovascular evidence
based on completed trial data
| Drug | Cardiovascular outcomes trial | Status |
|---|---|---|
| Semaglutide 2.4mg (Wegovy) | SELECT (NEJM, 2023, n=17,604) | Completed — 20% MACE reduction proven |
| Tirzepatide (Zepbound / Mounjaro) | Trial matching SELECT's design | Underway, not yet published as of 2026 |
4. Check whether you actually fit the studied population
SELECT's benefit was demonstrated in people with existing cardiovascular disease. If you're metabolically healthy with no cardiac history and no diabetes, you're outside the population that trial measured — the drug may still help your metabolic markers, but you shouldn't expect the same 20% MACE reduction number to apply to you personally.
Common mistake: quoting the 20% figure as if it applies to anyone taking semaglutide for any reason. It's a relative risk reduction in a specific, higher-risk cohort.
5. Track blood pressure and resting heart rate through titration
Semaglutide trials showed modest average reductions in systolic blood pressure, generally in the 3-6 mmHg range, alongside a small increase in resting heart rate of roughly 2-4 beats per minute. Neither is dangerous for most patients, but both should be tracked, not assumed. If your resting heart rate climbs meaningfully during dose escalation, that's a data point for your clinician, not something to self-manage.
Semaglutide trials showed modest average reductions in systolic blood pressure (3-6 mmHg) alongside a small increase in resting heart rate (2-4 bpm). Neither is dangerous for most patients, but both should be tracked, not assumed — a meaningfully rising resting heart rate during dose escalation is a data point for your clinician, not something to self-manage.
6. Separate the weight-loss effect from the direct cardiovascular effect
Ask your clinician to walk through your lipid panel and inflammatory markers (hs-CRP, if drawn) before and after starting therapy. Improvement that shows up before substantial weight loss suggests a direct vascular or anti-inflammatory mechanism — a distinct, real finding from the SELECT data, not marketing language.
7. Reassess with a full lab panel at 3 and 6 months
A1c, lipid panel, blood pressure trend, and weight should all be reviewed together, not weight alone. If your metabolic syndrome markers aren't improving alongside the weight loss, that's worth a protocol conversation, not a shrug.
Troubleshooting
"My cholesterol didn't drop as much as I expected." LDL and triglyceride improvements in trials were often modest and correlated with weight loss magnitude — a 5% weight loss won't produce the same lipid shift as 15%. Recheck the panel at 6 months before concluding anything.
"My resting heart rate went up and it's freaking me out." A 2-4 bpm increase is documented in trial data and generally not dangerous. A sustained increase beyond that, or new palpitations, is a reason to call your clinician, not wait for your next scheduled visit.
"I don't have heart disease — does any of this apply to me?" Partially. You may still see improved blood pressure, lipids, and inflammatory markers, but the specific 20% MACE reduction from SELECT was measured in people with existing cardiovascular disease, not in a healthy-heart population.
"I'm on tirzepatide and want the same cardiovascular claim as semaglutide." You can't have it yet — the trial data isn't there. Mechanistically plausible is not the same as proven.
"My blood pressure barely moved." Average trial reductions were modest, not dramatic. If you started with well-controlled blood pressure, there's less room to move; the effect is more pronounced in people who started elevated.
The cardiovascular case for GLP-1 therapy isn't really a weight-loss story dressed up as heart health — it's a separate mechanism that happens to travel with the same drug.
Tools and resources
- Metabolic syndrome: what it is and how a doctor treats it — for understanding the cluster of markers cardiovascular risk sits inside
- Ozempic vs. Wegovy: what is the difference — same drug, different labeled uses, relevant to which trial data applies to your prescription
- How to choose between tirzepatide and semaglutide — includes the evidence gap discussed above
- A recent lipid panel, blood pressure log, and A1c — the three data points your clinician needs to interpret any of this for your case specifically
What to do next
If you're weighing side effects against benefit in the first weeks of therapy, what to expect from GLP-1 side effects in the first month covers the timeline most patients go through before the cardiovascular and metabolic gains become visible in labs.
FAQ
What are the confirmed glp-1 cardiovascular benefits from clinical trials? The strongest confirmed benefit comes from the SELECT trial (2023): semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in adults with existing cardiovascular disease and overweight or obesity, without diabetes. Other GLP-1s have supportive but less complete data.
Does semaglutide reduce heart attack risk? In the SELECT trial population — people with established heart disease — semaglutide reduced the composite risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% over roughly three years.
Is tirzepatide proven to lower cardiovascular risk the same way semaglutide is? No. Tirzepatide lacks a completed cardiovascular outcomes trial matching SELECT's design as of 2026, so its cardiovascular benefit is plausible but not yet proven at the same evidence level.
Do GLP-1 medications increase heart rate? Trial data shows a small average increase in resting heart rate, roughly 2-4 beats per minute, during GLP-1 therapy. This is generally not clinically significant but should be tracked.
How much does semaglutide lower blood pressure? Trial averages show systolic blood pressure reductions in the 3-6 mmHg range, more pronounced in patients who started with elevated readings.
Do you need existing heart disease to get cardiovascular benefit from a GLP-1? The proven 20% MACE reduction from SELECT applies specifically to people with established cardiovascular disease. Without that history, you may still see improved lipids and blood pressure, but the same risk-reduction figure doesn't directly apply.
How long before cardiovascular benefits from a GLP-1 show up? In SELECT, cardiovascular event curves began separating from placebo within months, before most weight loss had occurred, suggesting an early mechanism beyond weight change alone.
Is Ozempic the same as Wegovy for heart protection? Both contain semaglutide, but Wegovy is the dose and label studied in SELECT for cardiovascular risk reduction. Ozempic's diabetes-focused trials showed cardiovascular signal too, but the SELECT data specifically used the Wegovy dose in a non-diabetic population.
One last thing
The part of the SELECT data that gets skipped in most GLP-1 marketing: the cardiovascular benefit curves started separating before participants had lost most of their weight. That timing is the strongest evidence that semaglutide is doing something at the vessel and inflammation level independent of pounds lost — which means the cardiovascular case for GLP-1 therapy isn't really a weight-loss story dressed up as heart health. It's a separate mechanism that happens to travel with the same drug.
Related guides
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/